Company Overview and News

 
Renascor Resources reveals robust economics for its graphite project in South Australia

2018-03-14 proactiveinvestors.com.au
Renascor Resources Ltd (ASX:RNU) has completed a pre-feasibility study (PFS) for its Siviour Graphite Project in South Australia, confirming robust project economics.
Upvote Downvote

 
Renascor Resources raising funds for Australia's largest graphite deposit

2017-09-19 proactiveinvestors.com.au
Renascor Resources Ltd (ASX:RNU) is developing Australia's largest graphite deposit, with the Tier-1 asset known as the Siviour project.
Upvote Downvote

 
Renascor Resources, Santana Minerals, Sayona Mining, Triangle Energy - Noosa latest

2017-07-19 proactiveinvestors.com.au
The Siviour Project in Southern Australia “looks like a tier-one graphite deposit”, according to Rob Murdoch, chief executive of the asset’s owner, Renascor Resources (ASX:RNU). 
Upvote Downvote

 
Renascor Resources shares rise on positive Siviour Graphite study

2017-05-23 proactiveinvestors.com.au
Renascor Resources (ASX:RNU) has released a positive scoping study for a proposed open pit mine and graphite production plant at the Siviour Graphite Deposit in South Australia’s Eyre Peninsula.
Upvote Downvote

 
Renascor Resources looks to upgrade Australia’s largest graphite deposit

2017-03-07 proactiveinvestors.com.au
Renascor Resources (ASX:RNU) has intersected multiple near-surface intersections of high-grade graphite from drilling at the Siviour Deposit within the Arno Graphite Project in South Australia.
Upvote Downvote

 
Renascor Resources Ltd drills Australia’s largest graphite deposit

2016-07-21 proactiveinvestors.com.au
Renascor Resources Ltd (ASX:RNU) has recommenced drilling at the Siviour Deposit within the Arno Graphite Project in South Australia’s Eyre Peninsula, aimed at upgrading the current resource. The Siviour deposit already ranks as the largest and highest grade graphite mineral deposit in Australia, with a high proportion in valuable jumbo and super-jumbo flake categories. The indicated and inferred mineral resource at Siviour is 16.
Upvote Downvote

 
Renascor Resources Ltd set to grow Australia's largest graphite resource

2016-07-14 proactiveinvestors.com.au
Renascor Resources Limited's (ASX:RNU) flagship project is the Arno Graphite Project, located within South Australia's Eyre Peninsula.
Upvote Downvote

 
Renascor raises $1.1m

2016-05-11 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

 
Renascor raises $1.1m

2016-05-11 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

 
Renascor Resources Ltd raising funds for graphite drilling

2016-05-09 proactiveinvestors.com.au
Renascor Resources Limited's (ASX:RNU) flagship project is the Arno Graphite Project, located within South Australia's Eyre Peninsula.
Upvote Downvote

 
Trading Halt

2016-05-09 asx.com.au
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...